AU2006216510A1 - Small molecule inhibitors of STAT3 and the uses thereof - Google Patents

Small molecule inhibitors of STAT3 and the uses thereof Download PDF

Info

Publication number
AU2006216510A1
AU2006216510A1 AU2006216510A AU2006216510A AU2006216510A1 AU 2006216510 A1 AU2006216510 A1 AU 2006216510A1 AU 2006216510 A AU2006216510 A AU 2006216510A AU 2006216510 A AU2006216510 A AU 2006216510A AU 2006216510 A1 AU2006216510 A1 AU 2006216510A1
Authority
AU
Australia
Prior art keywords
apoptosis
sta
stat3
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006216510A
Other languages
English (en)
Inventor
Jiayuh Lin
Hui Song
Renxiao Wang
Shaomeng Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of AU2006216510A1 publication Critical patent/AU2006216510A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2006216510A 2005-02-25 2006-02-24 Small molecule inhibitors of STAT3 and the uses thereof Abandoned AU2006216510A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65659705P 2005-02-25 2005-02-25
US60/656,597 2005-02-25
PCT/US2006/006637 WO2006091837A2 (en) 2005-02-25 2006-02-24 Small molecule inhibitors of stat3 and the uses thereof

Publications (1)

Publication Number Publication Date
AU2006216510A1 true AU2006216510A1 (en) 2006-08-31

Family

ID=36928057

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006216510A Abandoned AU2006216510A1 (en) 2005-02-25 2006-02-24 Small molecule inhibitors of STAT3 and the uses thereof

Country Status (7)

Country Link
US (1) US20060247318A1 (enExample)
EP (1) EP1853242A4 (enExample)
JP (1) JP2008535785A (enExample)
CN (1) CN101511179A (enExample)
AU (1) AU2006216510A1 (enExample)
CA (1) CA2599393A1 (enExample)
WO (1) WO2006091837A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1934331A4 (en) 2005-10-14 2009-01-21 Musc Found For Res Dev TARGETING PAX2 TO INDUCE CANCER TREATMENT AND TUMOR IMMUNITY INDUCED BY DEFB1
US7857804B2 (en) * 2006-09-01 2010-12-28 Mccaffrey Timothy A Use of Bcl inhibitors for the prevention of fibroproliferative reclosure of dilated blood vessels and other iatrogenic fibroproliferative disorders
DK2120958T3 (da) * 2006-12-06 2013-07-01 Univ Central Florida Res Found Stat3-inhibitor med anticancer-aktivitet og associerede fremgangsmåder
NZ578164A (en) * 2007-01-16 2011-12-22 Musc Found For Res Dev Compositions and methods for diagnosing, treating, and preventing prostate conditions
WO2009032338A1 (en) * 2007-09-09 2009-03-12 University Of Florida Research Foundation Apratoxin therapeutic agents: mechanism and methods of treatment
WO2009032351A1 (en) * 2007-09-09 2009-03-12 University Of Florida Research Foundation Natural product agents, derivatives, and methods of treatment
JP5688840B2 (ja) 2007-09-10 2015-03-25 ボストン バイオメディカル， インコーポレイテッド 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
US20090082470A1 (en) 2007-09-24 2009-03-26 Rafal Farjo Stat3 inhibiting compositions and methods
US8450337B2 (en) 2008-09-30 2013-05-28 Moleculin, Llc Methods of treating skin disorders with caffeic acid analogs
LT2547205T (lt) 2010-03-19 2024-06-10 1Globe Biomedical Co., Ltd. Nauji tikslinio poveikio vėžio kamieninėms ląstelėms būdai
KR101273747B1 (ko) * 2010-09-09 2013-06-12 가톨릭대학교 산학협력단 Ｓｔａ-21을 유효성분으로 함유하는 관절염의 예방 및 치료용 조성물
CN102961374B (zh) * 2012-12-12 2015-01-14 苏州大学 一种化合物的应用以及stat3抑制剂
MX2015014181A (es) 2013-04-09 2016-05-24 Boston Biomedical Inc 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer.
US11406707B2 (en) 2014-02-10 2022-08-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. STAT3 phosphorylation during graft-versus-host disease
CN104693280A (zh) * 2015-04-06 2015-06-10 苏州普罗达生物科技有限公司 信号传导及转录激活因子抑制多肽及其应用
CN104725480A (zh) * 2015-04-06 2015-06-24 苏州普罗达生物科技有限公司 一种信号传导及转录激活因子抑制多肽及其应用
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
CN106822898B (zh) * 2017-02-17 2018-09-25 王晓华 靶向下调stat3基因表达在提高肺腺癌化疗敏感性方面的应用
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
CN109988125B (zh) * 2018-10-25 2022-03-18 河南省锐达医药科技有限公司 一类新型苯甲酰苯胺化合物的制备方法和在肿瘤治疗上的应用
CA3135802A1 (en) 2019-04-05 2020-10-08 Kymera Therapeutics, Inc. Stat degraders and uses thereof
WO2021232067A1 (en) * 2020-05-15 2021-11-18 Glg Pharma, Llc Stats3 inhibition for treatment and prevention of human coronavirus infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4491588A (en) * 1982-03-31 1985-01-01 University Of Tennessee Research Corporation Treatment of psoriasis and seborrheic dermatitis with imidazole antibiotics
WO2000044774A2 (en) * 1999-01-27 2000-08-03 The University Of South Florida Inhibition of stat3 signal transduction for human cancer therapy

Also Published As

Publication number Publication date
JP2008535785A (ja) 2008-09-04
WO2006091837A3 (en) 2009-04-16
US20060247318A1 (en) 2006-11-02
EP1853242A4 (en) 2009-11-18
CN101511179A (zh) 2009-08-19
EP1853242A2 (en) 2007-11-14
WO2006091837A2 (en) 2006-08-31
CA2599393A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
US7432300B2 (en) Gossypol co-crystals and the use thereof
US20060247318A1 (en) Small molecule inhibitors of STAT3 and the uses thereof
US10842791B2 (en) Small molecule inhibitors of EGFR and PI3K
US20090118377A1 (en) Apogossypolone and the uses thereof
US20060084647A1 (en) Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof
US20100093645A1 (en) SMAC Peptidomimetics and the Uses Thereof
US20090010878A1 (en) Pulsatile dosing of gossypol for treatment of disease
EP2831067B1 (en) Small molecule inhibitors of mcl-1 and uses thereof
US20190002460A1 (en) Small molecule inhibitors of egfr and pi3k
US20200078360A1 (en) Small molecule dual inhibitors of egfr/pi3k and uses thereof
US20060247305A1 (en) Chromen-4-one inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof
US10308656B2 (en) Small molecule inhibitors of Ku70/80 and uses thereof
US20240124419A1 (en) Small molecule inhibitors of grp78 and uses thereof
US20220274991A1 (en) Small molecule inhibitors of ku70/80 and uses thereof
EP3285583B1 (en) Small molecule inhibitors of mcl-1 and uses thereof
HK1248520B (en) Quinazoline compounds as inhibitors of egfr and pi3k

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted